These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 30396656)
1. Dedicated breast PET value to evaluate BI-RADS 4 breast lesions. Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares A; Ruibal A; Vázquez-Caruncho M Eur J Radiol; 2018 Nov; 108():201-207. PubMed ID: 30396656 [TBL] [Abstract][Full Text] [Related]
2. Reproducibility assessment of uptake on dedicated breast PET for noise discrimination. Yuge S; Miyake KK; Ishimori T; Kataoka M; Matsumoto Y; Fujimoto K; Sugie T; Toi M; Nakamoto Y Ann Nucl Med; 2023 Feb; 37(2):121-130. PubMed ID: 36434200 [TBL] [Abstract][Full Text] [Related]
3. Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ? Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares Á; Vázquez-Caruncho M Eur Radiol; 2020 Jan; 30(1):514-522. PubMed ID: 31375867 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of dedicated breast positron emission tomography. Hashimoto R; Akashi-Tanaka S; Watanabe C; Masuda H; Taruno K; Takamaru T; Ide Y; Kuwayama T; Kobayashi Y; Takimoto M; Nakamura S Breast Cancer; 2022 Nov; 29(6):1013-1021. PubMed ID: 35768684 [TBL] [Abstract][Full Text] [Related]
5. Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors. Sasada S; Kimura Y; Masumoto N; Emi A; Kadoya T; Arihiro K; Okada M Eur J Surg Oncol; 2021 Jul; 47(7):1588-1592. PubMed ID: 33685728 [TBL] [Abstract][Full Text] [Related]
6. Higher breast cancer conspicuity on dbPET compared to WB-PET/CT. Nishimatsu K; Nakamoto Y; Miyake KK; Ishimori T; Kanao S; Toi M; Togashi K Eur J Radiol; 2017 May; 90():138-145. PubMed ID: 28583624 [TBL] [Abstract][Full Text] [Related]
7. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study. Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M Eur J Surg Oncol; 2018 Apr; 44(4):444-448. PubMed ID: 29396328 [TBL] [Abstract][Full Text] [Related]
8. The feasibility of dedicated breast PET for the assessment of residual tumor after neoadjuvant chemotherapy. Koyasu H; Goshima S; Noda Y; Nishibori H; Takeuchi M; Matsunaga K; Yamada T; Matsuo M Jpn J Radiol; 2019 Jan; 37(1):81-87. PubMed ID: 30392134 [TBL] [Abstract][Full Text] [Related]
9. Quantitative DWI implemented after DCE-MRI yields increased specificity for BI-RADS 3 and 4 breast lesions. Dijkstra H; Dorrius MD; Wielema M; Pijnappel RM; Oudkerk M; Sijens PE J Magn Reson Imaging; 2016 Dec; 44(6):1642-1649. PubMed ID: 27273694 [TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer. Masumoto N; Kadoya T; Sasada S; Emi A; Arihiro K; Okada M Breast Cancer Res Treat; 2018 Sep; 171(2):315-323. PubMed ID: 29779072 [TBL] [Abstract][Full Text] [Related]
12. Comparison of dedicated breast positron emission tomography and whole-body positron emission tomography/computed tomography images: a common phantom study. Satoh Y; Motosugi U; Imai M; Onishi H Ann Nucl Med; 2020 Feb; 34(2):119-127. PubMed ID: 31768819 [TBL] [Abstract][Full Text] [Related]
13. Assessment of BI-RADS category 4 lesions detected with screening mammography and screening US: utility of MR imaging. Strobel K; Schrading S; Hansen NL; Barabasch A; Kuhl CK Radiology; 2015 Feb; 274(2):343-51. PubMed ID: 25271857 [TBL] [Abstract][Full Text] [Related]
14. [Stereotactic Mammotome breast biopsy: routine clinical experience and correlation with BI-RADS--classification and histopathology]. Michel SC; Löw R; Singer G; Otto R; Hohl M; Kubik RA Praxis (Bern 1994); 2007 Sep; 96(39):1459-74. PubMed ID: 17966279 [TBL] [Abstract][Full Text] [Related]
15. Can strain elastography combined with ultrasound breast imaging reporting and data system be a more effective method in the differentiation of benign and malignant breast lesions? Arslan S; Uslu N; Ozturk FU; Akcay EY; Tezcaner T; Agildere AM J Med Ultrason (2001); 2017 Oct; 44(4):289-296. PubMed ID: 28154989 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of combined BI-RADS analysis and Nakagami statistics of ultrasound echoes in the diagnosis of breast lesions. Dobruch-Sobczak K; Piotrzkowska-Wróblewska H; Roszkowska-Purska K; Nowicki A; Jakubowski W Clin Radiol; 2017 Apr; 72(4):339.e7-339.e15. PubMed ID: 28038779 [TBL] [Abstract][Full Text] [Related]
17. US and MRI in the evaluation of mammographic BI-RADS 4 and 5 microcalcifications. Hrkac Pustahija A; Ivanac G; Brkljacic B Diagn Interv Radiol; 2018 Jul; 24(4):187-194. PubMed ID: 30091708 [TBL] [Abstract][Full Text] [Related]
19. Which type of breast cancers is undetectable on ring-type dedicated breast PET? Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M Clin Imaging; 2018; 51():186-191. PubMed ID: 29859482 [TBL] [Abstract][Full Text] [Related]
20. A Pivotal Study of Optoacoustic Imaging to Diagnose Benign and Malignant Breast Masses: A New Evaluation Tool for Radiologists. Neuschler EI; Butler R; Young CA; Barke LD; Bertrand ML; Böhm-Vélez M; Destounis S; Donlan P; Grobmyer SR; Katzen J; Kist KA; Lavin PT; Makariou EV; Parris TM; Schilling KJ; Tucker FL; Dogan BE Radiology; 2018 May; 287(2):398-412. PubMed ID: 29178816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]